PepGen Inc. (PEPG) Form 8-K — May 12, 2026
PepGen Inc. reported its financial results for the quarter ended March 31, 2026, with a net loss of $17.8 million, or $(0.26) per share, compared to a net loss of $30.2 million, or $(0.92) per share, in the same period of 2025. The company also announced a significant reduction in R&D expenses, from $25.4 million to $13.0 million, and G&A expenses remained stable at $5.9 million. The 5 mg/kg cohort of the FREEDOM2-DM1 trial demonstrated favorable safety, splicing, and vHOT data, supporting the potential of the ongoing 10 mg/kg dose cohort.
Key figures
- Eps
- -0.26
- Eps Beat
- 0
- Revenue
- 0
- Guidance
- sufficient to fund operations through FREEDOM2 12.5 mg/kg MAD readout and into 2H 2027
- Net Income
- -17,763
- Total Debt
- 0
- Revenue Yoy
- 0
- Cash Position
- 132,303
- Shares Outstanding
- 69,091,100
- Liabilities
- 22,315
- Total Assets
- 156,295
- Operating Loss
- 18,942
- Interest Income
- 1,250
- Other Income Net
- 1,194
- Income Tax Expense
- 15
- Stockholders Equity
- 133,980
- Net Loss Before Income Tax
- 17,748
- Total Operating Expenses
- 18,942
- Research And Development Expenses
- 13,004
- General And Administrative Expenses
- 5,938
Price after filing
Close on the filing date to close N calendar days later (from $1.68). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.